OrbiMed’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,665,115
Closed -$47.1M 126
2024
Q3
$47.1M Sell
1,665,115
-940,500
-36% -$24.2M 0.86% 35
2024
Q2
$49.8M Hold
2,605,615
0.98% 33
2024
Q1
$85.4M Sell
2,605,615
-140,917
-5% -$4.5M 1.56% 20
2023
Q4
$90.7M Sell
2,746,532
-149,100
-5% -$4.22M 1.81% 16
2023
Q3
$78.8M Hold
2,895,632
1.67% 20
2023
Q2
$87.7M Hold
2,895,632
1.59% 18
2023
Q1
$94M Buy
2,895,632
+70,800
+3% +$2.24M 1.84% 15
2022
Q4
$79.3M Buy
2,824,832
+830,115
+42% +$23.8M 1.52% 19
2022
Q3
$71.7K Buy
1,994,717
+216,717
+12% +$7.63M 1.33% 26
2022
Q2
$54.6K Buy
1,778,000
+378,000
+27% +$11M 0.99% 34
2022
Q1
$45.2M Buy
1,400,000
+462,000
+49% +$12.1M 0.73% 43
2021
Q4
$26M Buy
938,000
+593,000
+172% +$17M 0.33% 72
2021
Q3
$10.7M Buy
+345,000
New +$8.28M 0.12% 124

Other funds holding EVH

OrbiMed's EVH Position: Q4 2024 in Review

OrbiMed sold out of Evolent Health (EVH) in Q4 2024, closing a stake of 1,665,115 shares — an estimated $47.1M sold.

OrbiMed first reported a position in EVH in Q3 2021 and held it in 13 quarters. The position peaked at $94M in Q1 2023. 240 funds tracked by Wall St. Rank hold EVH as of Q4 2024.

  • OrbiMed reported no remaining Evolent Health position as of Q4 2024 after selling out during the quarter.
  • OrbiMed sold 1,665,115 Evolent Health shares in Q4 2024, an estimated $47.1M.
  • OrbiMed first reported a position in Evolent Health in Q3 2021 and held it in 13 quarters.
  • OrbiMed's Evolent Health position peaked at $94M in Q1 2023.
  • 240 funds tracked by Wall St. Rank held Evolent Health as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.